CDKN2A and neoplasm: We observed similar phenotypic differences in tumor burden when comparing WT and Atg12ECKO or Atg9ECKO mice inoculated with B16‐F10 or the immunogenic YUMMER 1.7 melanoma cells, carrying the BrafV600E/Pten−/−/Cdkn2a−/− mutations, respectively (Fig 1E–H).